ReShape Capital Stock vs Current Deferred Revenue Analysis

RSLS Stock

USD 0.23 0.02 8.00%

ReShape Lifesciences financial indicator trend analysis is much more than just breaking down ReShape Lifesciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ReShape Lifesciences is a good investment. Please check the relationship between ReShape Lifesciences Capital Stock and its Current Deferred Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

Capital Stock vs Current Deferred Revenue

Capital Stock vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ReShape Lifesciences Capital Stock account and Current Deferred Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between ReShape Lifesciences' Capital Stock and Current Deferred Revenue is -0.43. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of ReShape Lifesciences, assuming nothing else is changed. The correlation between historical values of ReShape Lifesciences' Capital Stock and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of ReShape Lifesciences are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Capital Stock i.e., ReShape Lifesciences' Capital Stock and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.43

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Capital Stock

The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from ReShape Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ReShape Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.At this time, ReShape Lifesciences' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.20 in 2024, whereas Tax Provision is likely to drop (36.8 K) in 2024.

ReShape Lifesciences fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Short Term Debt
Total Assets		0.97	-0.13	0.73	-0.31	0.34	0.57	-0.12	-0.31	0.15	0.23	-0.3	0.34	0.21	0.92	0.37	-0.18	0.2	0.25	0.12	0.44	0.09	0.17	-0.31	0.26	0.22
Total Stockholder Equity	0.97		-0.13	0.8	-0.24	0.31	0.37	-0.16	-0.43	0.0	0.21	-0.32	0.27	0.21	0.9	0.42	-0.19	0.2	0.19	0.09	0.34	0.07	0.15	-0.23	0.26	0.18
Retained Earnings	-0.13	-0.13		0.08	-0.48	-0.91	-0.08	0.73	0.02	-0.39	-0.31	-0.22	-0.69	0.47	-0.17	0.25	-0.5	0.47	-0.73	0.52	0.42	-0.02	-0.4	0.51	0.19	0.3
Other Assets	0.73	0.8	0.08		-0.15	0.05	0.11	-0.18	-0.5	-0.37	-0.12	-0.08	-0.09	0.0	0.78	0.29	-0.37	-0.01	-0.14	0.16	0.44	-0.14	-0.14	-0.06	-0.03	0.01
Common Stock Shares Outstanding	-0.31	-0.24	-0.48	-0.15		0.2	-0.4	-0.23	-0.16	-0.09	-0.14	0.1	-0.06	-0.19	-0.31	-0.4	0.42	-0.18	0.04	-0.19	-0.48	-0.33	-0.11	-0.13	0.02	-0.28
Other Stockholder Equity	0.34	0.31	-0.91	0.05	0.2		0.24	-0.67	-0.02	0.39	0.36	0.13	0.76	-0.37	0.35	-0.1	0.4	-0.37	0.78	-0.43	-0.25	0.11	0.44	-0.51	-0.17	-0.19
Total Liab	0.57	0.37	-0.08	0.11	-0.4	0.24		0.09	0.3	0.62	0.18	-0.07	0.42	0.1	0.49	0.0	-0.02	0.1	0.35	0.17	0.59	0.12	0.13	-0.41	0.11	0.27
Short Long Term Debt Total	-0.12	-0.16	0.73	-0.18	-0.23	-0.67	0.09		-0.06	-0.08	-0.21	-0.19	-0.55	0.55	-0.23	0.1	-0.02	0.55	-0.53	0.47	0.38	-0.23	-0.26	0.42	0.35	0.54
Other Current Liab	-0.31	-0.43	0.02	-0.5	-0.16	-0.02	0.3	-0.06		0.41	0.44	-0.33	0.19	0.26	-0.48	-0.16	0.1	0.26	0.24	0.17	-0.04	0.09	0.45	-0.2	0.29	-0.47
Total Current Liabilities	0.15	0.0	-0.39	-0.37	-0.09	0.39	0.62	-0.08	0.41		0.41	0.02	0.62	-0.05	0.09	-0.36	0.44	-0.04	0.62	-0.34	-0.15	0.09	0.41	-0.25	0.11	-0.04
Property Plant And Equipment Net	0.23	0.21	-0.31	-0.12	-0.14	0.36	0.18	-0.21	0.44	0.41		-0.47	0.57	0.31	0.06	0.11	0.55	0.31	0.58	-0.18	-0.08	-0.02	0.98	0.03	0.48	-0.51
Net Debt	-0.3	-0.32	-0.22	-0.08	0.1	0.13	-0.07	-0.19	-0.33	0.02	-0.47		0.2	-0.92	0.09	-0.5	0.06	-0.93	0.19	-0.49	0.05	0.01	-0.4	0.23	-0.95	0.08
Accounts Payable	0.34	0.27	-0.69	-0.09	-0.06	0.76	0.42	-0.55	0.19	0.62	0.57	0.2		-0.38	0.4	-0.19	0.39	-0.38	0.96	-0.57	-0.09	0.35	0.56	-0.21	-0.18	-0.31
Cash	0.21	0.21	0.47	0.0	-0.19	-0.37	0.1	0.55	0.26	-0.05	0.31	-0.92	-0.38		-0.16	0.47	-0.06	1.0	-0.36	0.6	0.11	-0.1	0.24	-0.03	0.94	0.15
Non Current Assets Total	0.92	0.9	-0.17	0.78	-0.31	0.35	0.49	-0.23	-0.48	0.09	0.06	0.09	0.4	-0.16		0.19	-0.19	-0.16	0.3	-0.09	0.49	0.09	0.02	-0.14	-0.12	0.21
Non Currrent Assets Other	0.37	0.42	0.25	0.29	-0.4	-0.1	0.0	0.1	-0.16	-0.36	0.11	-0.5	-0.19	0.47	0.19		-0.43	0.45	-0.31	0.4	0.09	0.42	0.02	-0.3	0.37	0.27
Long Term Debt	-0.18	-0.19	-0.5	-0.37	0.42	0.4	-0.02	-0.02	0.1	0.44	0.55	0.06	0.39	-0.06	-0.19	-0.43		-0.07	0.45	-0.49	-0.23	-0.33	0.61	0.21	0.12	-0.32
Cash And Short Term Investments	0.2	0.2	0.47	-0.01	-0.18	-0.37	0.1	0.55	0.26	-0.04	0.31	-0.93	-0.38	1.0	-0.16	0.45	-0.07		-0.36	0.6	0.1	-0.1	0.24	-0.03	0.94	0.15
Net Receivables	0.25	0.19	-0.73	-0.14	0.04	0.78	0.35	-0.53	0.24	0.62	0.58	0.19	0.96	-0.36	0.3	-0.31	0.45	-0.36		-0.55	-0.16	0.17	0.61	-0.19	-0.14	-0.38
Common Stock Total Equity	0.12	0.09	0.52	0.16	-0.19	-0.43	0.17	0.47	0.17	-0.34	-0.18	-0.49	-0.57	0.6	-0.09	0.4	-0.49	0.6	-0.55		0.39	-0.24	-0.23	-0.22	0.45	0.36
Non Current Liabilities Total	0.44	0.34	0.42	0.44	-0.48	-0.25	0.59	0.38	-0.04	-0.15	-0.08	0.05	-0.09	0.11	0.49	0.09	-0.23	0.1	-0.16	0.39		-0.14	-0.13	0.16	-0.05	0.3
Other Current Assets	0.09	0.07	-0.02	-0.14	-0.33	0.11	0.12	-0.23	0.09	0.09	-0.02	0.01	0.35	-0.1	0.09	0.42	-0.33	-0.1	0.17	-0.24	-0.14		-0.09	-0.27	-0.11	0.11
Property Plant And Equipment Gross	0.17	0.15	-0.4	-0.14	-0.11	0.44	0.13	-0.26	0.45	0.41	0.98	-0.4	0.56	0.24	0.02	0.02	0.61	0.24	0.61	-0.23	-0.13	-0.09		0.01	0.41	-0.54
Preferred Stock Total Equity	-0.31	-0.23	0.51	-0.06	-0.13	-0.51	-0.41	0.42	-0.2	-0.25	0.03	0.23	-0.21	-0.03	-0.14	-0.3	0.21	-0.03	-0.19	-0.22	0.16	-0.27	0.01		-0.16	-0.11
Total Current Assets	0.26	0.26	0.19	-0.03	0.02	-0.17	0.11	0.35	0.29	0.11	0.48	-0.95	-0.18	0.94	-0.12	0.37	0.12	0.94	-0.14	0.45	-0.05	-0.11	0.41	-0.16		0.0
Short Term Debt	0.22	0.18	0.3	0.01	-0.28	-0.19	0.27	0.54	-0.47	-0.04	-0.51	0.08	-0.31	0.15	0.21	0.27	-0.32	0.15	-0.38	0.36	0.3	0.11	-0.54	-0.11	0.0

Click cells to compare fundamentals

ReShape Lifesciences Account Relationship Matchups

ReShape Lifesciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	39.7M	37.1M	54.3M	11.1M	10.7M	10.2M
Total Stockholder Equity	24.1M	14.5M	46.1M	3.7M	6.7M	6.3M
Retained Earnings	(493.2M)	(514.8M)	(576.8M)	(624.2M)	(635.6M)	(603.8M)
Other Assets	99K	46K	1.5M	102K	117.3K	111.4K
Common Stock Shares Outstanding	31.4K	26.0K	218.5K	424.4K	6.0M	6.3M
Liabilities And Stockholders Equity	39.7M	37.1M	54.3M	11.1M	10.7M	10.2M
Other Stockholder Equity	517.3M	529.4M	622.9M	627.9M	642.3M	323.4M
Total Liab	15.6M	22.6M	8.2M	7.5M	4.1M	3.9M
Short Long Term Debt Total	768K	477K	279K	171K	262K	248.9K
Other Current Liab	5.6M	7.2M	3.0M	4.9M	1.3M	1.3M
Total Current Liabilities	10.4M	11.6M	7.3M	7.5M	3.8M	6.0M
Property Plant And Equipment Net	774K	1.0M	1.7M	869K	310K	600.4K
Net Debt	(2.2M)	(2.5M)	(22.5M)	(3.7M)	(4.3M)	(4.5M)
Accounts Payable	4.3M	3.7M	3.5M	1.9M	1.7M	1.3M
Cash	2.9M	3.0M	22.8M	3.9M	4.6M	4.3M
Non Current Assets Total	29.5M	28.1M	24.0M	1.2M	431K	409.5K
Non Currrent Assets Other	562.9K	99K	46K	1.5M	29K	27.6K
Cash And Short Term Investments	2.9M	3.0M	22.8M	3.9M	4.6M	4.3M
Net Receivables	4.1M	2.6M	2.8M	2.2M	1.7M	997.2K
Non Current Liabilities Total	5.2M	11.0M	855K	2.6M	287.0K	272.6K
Other Current Assets	1.7M	1.1M	1.6M	84K	337K	320.2K
Property Plant And Equipment Gross	774K	1.0M	1.7M	1.2M	400K	618.1K
Total Current Assets	10.1M	8.9M	30.3M	9.9M	10.3M	16.2M
Accumulated Other Comprehensive Income	(8K)	(121K)	(92K)	(88K)	(79.2K)	(83.2K)
Short Term Debt	291K	314K	279K	171K	111K	105.5K
Common Stock	8K	6K	18K	1K	23K	21.9K
Property Plant Equipment	16K	584K	1.7M	869K	782.1K	565.6K
Other Liab	6.2M	4.7M	1.6M	855K	983.3K	934.1K
Current Deferred Revenue	352K	202K	398K	549K	639K	671.0K
Inventory	1.3M	2.2M	3.0M	3.6M	3.7M	3.9M
Net Tangible Assets	(4.6M)	(12.5M)	25.2M	3.4M	3.1M	4.0M
Retained Earnings Total Equity	(334.8M)	(419.0M)	(493.2M)	(514.8M)	(463.3M)	(486.5M)
Capital Surpluse	410.8M	450.6M	517.3M	529.4M	608.8M	386.1M
Deferred Long Term Liab	5.3M	1.8M	702K	615K	707.3K	929.9K
Intangible Assets	28.7M	27.0M	20.8M	260K	299K	284.1K

Pair Trading with ReShape Lifesciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ReShape Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReShape Lifesciences will appreciate offsetting losses from the drop in the long position's value.

Moving against ReShape Stock

0.64	EVH	Evolent Health	Pair Corr
0.59	DH	Definitive Healthcare	Pair Corr
0.54	VEEV	Veeva Systems Class	Pair Corr
0.5	AMN	AMN Healthcare Services	Pair Corr
0.49	XTNT	Xtant Medical Holdings	Pair Corr

The ability to find closely correlated positions to ReShape Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ReShape Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ReShape Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ReShape Lifesciences to buy it.

The correlation of ReShape Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ReShape Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ReShape Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ReShape Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC